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Abstract
Recent studies have identified the mutational landscape of pancreatic cancer and 
suggested tumor‐specific subtypes. However, the major hurdle against personalized 
treatment is the difficulty to obtain sufficient cancer tissues from most inoperable 
cases. We investigated whether patient‐derived conditionally reprogrammed cells 
(CRCs) can be constructed using a small piece of tumor tissue using endoscopic 
ultrasound (EUS)‐guided fine needle biopsy (FNB). Thirty patients with pancreatic 
solid mass (mean size, 34.6 mm) were enrolled prospectively. Among 22 patients 
who were diagnosed with pancreatic ductal adenocarcinoma, we established patient‐
derived pancreatic cancer cell lines from eight patients (36.4%). Immunofluorescence 
colony staining for CRCs showed that the cytoplasm of cancer cells was clearly 
stained with anti‐cytokeratin 19 monoclonal antibody. In the soft agar colony for-
mation assay, CRCs formed colonies compared with the negative control by day 
15. In vivo, implanted CRCs showed tumor engraftment and hematoxylin and eosin 
staining showed pancreatic cancer ductal structure. All established CRCs showed a 
KRAS mutation. In conclusion, we established patient‐derived pancreatic cancer cell 
lines with a small tumor tissue obtained by EUS‐FNB. With in vitro drug sensitivity 
and genomic studies, established patient‐derived cell lines can be used in identifica-
tion of new targets for diagnosis and treatment of pancreatic cancer.
K E Y W O R D S
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1 |  INTRODUCTION
Recent advances in cancer genomics have driven a paradigm 
change in anticancer treatment toward personalized therapy 
according to the genetic signature of each patient.1,2 Next gen-
eration sequencing methods have identified genetic changes, 
including single nucleotide variants, and have allowed the 
classification of subtypes of pancreatic cancer according to 
their different treatment responses. To utilize these genetic 
features of pancreatic cancer, various recent preclinical mod-
els were introduced to pancreatic cancer research.3 The suc-
cessful application of preclinical cancer models derived from 
tumor tissue provides the opportunity for personalized drug 
selection and prognosis prediction.
For the establishment of preclinical cancer models, 
sufficient tumor tissue acquisition is essential. However, 
obtaining surgical specimens is extremely difficult in pan-
creatic cancer because only less than 15% of all patients 
with pancreatic cancer can be treated using surgical resec-
tion. The only reliable way to obtain the tissue sample is 
endoscopic ultrasound (EUS)‐guided fine needle biopsy 
(FNB) in most patients with advanced pancreatic cancer.4 
However, the amount of tissue obtained using EUS‐FNB is 
not enough to perform advanced laboratory or molecular 
analysis, including exome sequencing. Therefore, the es-
tablishment of a platform of primary cancer cell lines with 
the small piece of tumor tissue obtained using EUS‐FNB is 
urgently required.
In this study, we aimed to investigate whether patient‐de-
rived preclinical cancer models can be constructed using a 
small piece of tumor tissue obtained via EUS‐FNB in pan-
creatic adenocarcinoma.
2 |  MATERIALS AND METHODS
2.1 | Patients
Patients who underwent EUS‐guided tissue acquisition from 
a solid pancreatic mass at Severance hospital, South, Korea 
were prospectively enrolled from July 2016 to November 
2017. All pancreatic masses were previously diagnosed using 
computed tomography (CT), magnetic resonance imaging, or 
previously performed EUS. The inclusion criteria were as 
follows: (a) patients with a solid pancreatic mass that was 
visualized with EUS and was above 1 cm in size in imaging 
studies, (b) at least 20 years of age, and (c) provided writ-
ten informed consent. This study was performed in accord-
ance with the ethical guidelines of the 1975 Declaration of 
Helsinki and was approved by the institutional review board 
of the ethics committee of Severance Hospital and regis-
tered in a clinical trial database (ClinicalTrials.gov identifier: 
NCT03017599). All experiments were performed in accord-
ance with relevant guidelines.
2.2 | Procedural technique
EUS‐FNB was performed using a convex array endosono-
scope (GF‐UCT260; Olympus Co., Tokyo, Japan). Tissue ac-
quisition was performed using a 20‐gauge needle (EchoTip® 
ProCoreTM Endoscopic Ultrasound Needle, Cook Medical 
Inc, Bloomington, IN). Procedures were performed by five 
experienced endoscopists who had at least 5 years of experi-
ence and had each previously performed >500 endoscopic 
retrograde cholangiopancreatography procedures. Once the 
target lesion had been penetrated by the needle, the stylet 
was removed and negative suction pressure was applied for 
10‐20  seconds using a 10  mL syringe while more than 20 
to‐and‐fro movements within the lesion were made. Suction 
was then released by closing the lock of the syringe, and the 
needle was finally removed. After individual passes, the aspi-
rated specimen was expelled onto a glass slide by reinsertion 
of the stylet. The specimen was fixed in formalin after being 
immersed in normal saline to decrease the amount of blood if 
sufficient specimen size was confirmed by the endoscopist.
2.3 | Pathologic assessment of the 
obtained sample
One experienced pathologist, blinded to the clinical informa-
tion, made the pathologic diagnosis and evaluation of the spec-
imen quality for this study. A histologic core was defined as an 
architecturally intact piece of tissue measuring at least 550 µm 
in its greatest axis (corresponding approximately to the diame-
ter of a high power microscopic field).5,6 The pathology reports 
were divided into the following categories: (a) inadequate for 
diagnosis; (b) benign or atypical epithelium; (c) pancreatic duct 
adenocarcinoma or other neoplasm (a, b; negative for malig-
nancy and c; positive for malignancy).
The quality of obtained samples was evaluated using he-
matoxylin and eosin staining and the following three items 
were examined: quantity of tissue, degree of contamination, 
and amount of blood in the specimens. The quantity of tissue 
was assessed using the scoring system described by Gerke 
et al7 Briefly, a score of zero was a sample with no material, 
scores of 1‐2 were samples that enabled cytological evalua-
tion but did not provide histologic information, and scores 
of 3‐5 were samples that enabled histologic assessment.8,9 A 
final diagnosis of the pancreatic mass was made based on the 
histologic diagnosis in patients with surgical or biopsy speci-
mens or on clinical follow‐up for at least 6 months in patients 
with undetermined histologic results.
2.4 | Conditionally reprogrammed 
cell method
To generate patient‐derived pancreatic cell lines, we 
used the CRC method developed by the Schlegel group at 
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Georgetown. All tumor tissues obtained from the endoscopy 
room were placed in a medium containing antibiotics. Using 
a set of forceps and a scalpel, residual fat tissue was removed. 
Tumor tissues were minced into 1‐2  mm small fragments 
with sterile scissors. Primary cell line isolation was initiated 
within 1‐2 hours of tumor resection. Tissue samples were co-
cultured with J2 murine fibroblast feeder cells and medium 
containing the Rho‐kinase inhibitor (Y‐27632), as previously 
described.10,11
2.5 | Immunofluorescence assay
Cells were fixed in 4% paraformaldehyde for 15 minutes at 
room temperature and washed in PBS 3 times, followed by 
blocking with 5% normal goat serum for 1 hour and incuba-
tion with primary antibodies at room temperature (1 hour), 
washing three times in PBS, and incubation with second anti-
body for 30 minutes. The following primary antibodies were 
used for immunostaining: a‐amylase (A8273, rabbit poly-
clonal, dilution 1:100; Sigma, St. Louis, MO), cytokeratin 
19 (CK19) (A53‐B/A2: sc‐6278, mouse monoclonal, dilution 
1:100; Santa Cruz Biotechnology, Santa Cruz, CA), insulin 
(mouse monoclonal, dilution 1:100; Zymed, Waltham, MA), 
and vimentin (V9: sc‐6260, mouse monoclonal, dilution 
1:100; Santa Cruz Biotechnology). The cells were stained 
with Alexa Flour conjugated secondary antibodies from 
Invitrogen.
2.6 | In vitro and in vivo tumorigenicity
To evaluate tumorigenicity, in vitro tumorigenesis was ex-
amined using soft agar culture. The anchorage‐independent 
growth of CRCs was evaluated using a colony formation 
assay in soft agar. Soft agar colony formation assays were 
performed using the double‐layer soft agar method. In each 
well of a 6‐well plate, 5 × 104 cells were plated on the top 
agar (0.5% agarose gel) over a base agar (1% agarose gel). 
After 2‐3 weeks of incubation in soft agar, the average num-
bers of colonies formed by CRCs were checked.
F I G U R E  1  Flow chart. Diagnostic 
was defined as obtaining specimens 
sufficient for histologic interpretation. 
Nondiagnostic was defined as obtaining 
tissues insufficient for histologic 
interpretation. EUS, Endoscopic ultrasound; 
FNB, fine needle biopsy
T A B L E  1  Patient demographic and pancreatic mass 
characteristics
Variables Patients (n = 30)
Age, mean ± SD, (y) 65.2 ± 9.2
Men, no. (%) 16 (53.3%)
Location of mass, no. (%)
Head or neck 14 (46.7%)
Body or tail 16 (53.3%)
Size of mass on EUS, (mm)
Mean ± SD 34.6 (12.3)
Median 32
<20 mm, n 2 (6.7%)
≥20 mm, n 28 (93.3%)
Final diagnosis, no. (%)
Malignancy  
Pancreatic ductal adenocarcinomaa 24 (80.0%)
Neuroendocrine carcinoma 1 (3.3%)
Metastatic cancerb 2 (6.7%)
Benign disease  
IgG4‐related disease 1 (3.3%)
Autoimmune pancreatitis 1 (3.3%)
Chronic pancreatitis 1 (3.3%)
Abbreviation: EUS, Endoscopic ultrasound.
aTwo patients were diagnosed with pancreatic adenocarcinoma in the second 
study‐free EUS‐FNB and open pancreatic biopsy. 
bMetastatic cancer originated from lung cancer and Klatskin tumor. 
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To evaluate in vivo tumorigenicity, 2  ×  106 CRCs in 
0.2 mL of Matrigel (BD Biosciences) were injected subcutane-
ously into the flank regions of 5‐week‐old male nonobese dia-
betic/severe combined immunodeficiency (NOD/SCID) mice 
(Charles River Laboratories, Tokyo, Japan). Animals were 
housed at the Yonsei University animal care facility according 
to institutional guidelines. Monitoring for tumor growth was 
performed up to 3 months postimplantation. Tumor size was 
assessed by measurement with calipers once per week. Tumors 
were harvested once they reached 1.5 cm in diameter.
2.7 | KRAS mutation analysis by 
polymerase chain reaction
KRAS mutations, key mutations in pancreatic cancer, were 
analyzed using polymerase chain reaction (PCR). Genetic 
analysis of the KRAS gene was performed using PCR am-
plification of exon 1 (codons 12 and 13), followed by direct 
sequencing of the PCR products. DNA was extracted using 
QIAGEN QIAamp® DNA Mini Kits (Hilden, Germany). 
PCR primers for KRAS sequencing were as follows: forward, 
5'‐aggcctg ctgaaaatga ctga‐3'; and reverse, 5'‐ggtcctgcac 
cagtaatatg ca ‐3' (length: 164 bp). Each PCR mix contained 
forward and reverse primers (each 10  pmol), 200  µmol/L 
of of dNTP, 1 × PCR buffer (10 mmol/L tris‐HCl (pH 8.3), 
50  mmol/L KCl, 1.5  mmol/L MgCl2, 1 U of r‐Taq DNA 
polymerase (TaKaRa TaqTM, Takara Bio Inc, Japan), and 
1 μL of DNA in a total volume of 25 μL. PCR conditions 
consisted of initial denaturation at 95°C for 5 minutes; 30 cy-
cles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C 
for 30  seconds; and final extension at 72°C for 7 minutes. 
General sequencing was performed at COSMO Genetech 
(Cosmo Genetech Co., Ltd., Korea), and analyzed using an 
ABI 3730 (Applied Biosystems, USA).
2.8 | Statistical analysis
Continuous variables were expressed as mean  ±  SD, and 
categorical variables were expressed as proportions, n (%). 
A P < 0.05 on a Mann‐Whitney U test indicated statistical 
significance. Statistical analyses were performed using spss 
version 20.0 (SPSS, Chicago, IL).
3 |  RESULTS
3.1 | Patient characteristics
A total of 30 patients who underwent EUS‐FNB were prospec-
tively enrolled in this study (Figure 1). The characteristics of the 
patients and pancreatic solid masses are summarized in Table 
1. Their mean age was 65.2 years (men, 53.3%). Lesions were 
T A B L E  2  Technical characteristics and outcomes of EUS‐guided 
FNB
Variables Patients (n = 30)
Access route, no. (%)
Transgastric 13 (33.3%)
Transduodenal 17 (56.7%)
No. of needle passes, mean ± SD 2.5 ± 0.5
2 times, n 16 (53.3%)
3 times, n 14 (46.7%)
Failure to achieve diagnosis 2 (6.7%)
Diagnostic failure 2 (6.7%)
Technical failure 0 (0.0%)
Diagnostic accuracy 28 (93.3%)
Differentiation confirmed 15 (50.0%)
Well differentiated 1 (3.3%)
Moderately differentiated 12 (40.0%)
Poorly differentiated 2 (6.7%)
Complications 3 (10.0%)
Pancreatitis 2 (6.7%)
Fever 1 (3.3%)
Abbreviations: EUS, Endoscopic ultrasound; FNB, Fine needle biopsy; No, 
Number; SD, Standard deviation.
F I G U R E  2  Representative specimens. (A), All specimens 
were grossly verified to ensure that they were suitable for obtaining 
a histology‐based diagnosis by the endoscopist. (B), Conditionally 
reprogrammed cell formation after 15 days of culture
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located in the pancreatic head or neck (14 cases, 46.7%), body 
(10 cases, 33.3%), and tail (six cases, 20%). The mean size of the 
pancreatic masses was 34.6 ± 12.3 mm (range 14.2‐69.0 mm). 
Among the 30 enrolled patients, 24 (80%) were finally diag-
nosed with pancreatic ductal adenocarcinoma (PDAC). The 
technical characteristics and outcomes of EUS‐FNB are sum-
marized in Table 2. The procedure was feasible without any 
technical failure, and all specimens were grossly adequate tis-
sues to obtain a histology‐based diagnosis (Figure 2A).
3.2 | Acquisition of the qualified and 
sufficient tissue
The quality of the obtained specimens is summarized in 
Table 3. Sufficient quantity of tissues for histologic inter-
pretation (determined as the tissue quantity score from 3 to 
5) was shown in 93.3% of cases (28/30). In a patient with 
a tissue quantity score of 2, the cytological interpretation 
was suspicious adenocarcinoma, and he was histologically 
diagnosed with moderately differentiated adenocarcinoma 
in the second EUS‐FNB. The rate of the degree of con-
tamination lower than 25.0% was 86.7% (26/30), and the 
amount of blood in the specimen was minimal in 30.0% 
(9/30) and moderate in 36.7% (11/30) of cases.
EUS‐FNB showed a diagnostic accuracy of 93.3% (28 of 
30 cases); this consisted of 25 cases of pathologically con-
firmed malignancy (PDAC, 22 cases) and three cases of 
benign diseases (autoimmune pancreatitis, chronic pancreati-
tis, and IgG4‐related disease). Diagnostic failure occurred in 
two patients. One of these patients could not be diagnosed 
pathologically, even in the second study‐free EUS‐FNB trial. 
However, the patient was diagnosed with PDAC using direct 
biopsy under laparotomy in operating room and received che-
motherapy. Another patient was diagnosed with a few strips of 
atypical epithelium based on a pathological result; however, 
this patient was diagnosed with PDAC in the second study‐
free EUS‐FNB and also received chemotherapy (Table 2).
3.3 | Establishment of patient‐derived 
pancreatic cancer cell lines
Among 22 patients who were diagnosed with PDAC via 
EUS‐FNB, we established patient‐derived pancreatic cancer 
cell lines in eight patients (Figure 1). Table 4 shows the char-
acteristics of established CRCs using EUS‐FNB. Epithelial 
colonies were readily observed at 2  days and rapidly pro-
liferated to reach confluence in approximately 7‐14  days 
(Figure 2B). The karyotypes of patient‐derived CRCs were 
highly aneuploid, and it was maintained even when passing 
the passage (Figure S1). It demonstrates the genomic stabil-
ity in CRCs methods. Whole exome sequencing kept repre-
sentative key mutations including KRAS, p53, and CDKN2A 
(H.S. Lee, S.J. Park, J. Lee, M.J. Chung, J.Y. Park, S.W. Park, 
S.Y. Song, J.M. Han, S. Bang, unpublished data).
Quantity of tissue
0: sample with no material, n 0
Cytology (1‐2), n (%) 2 (6.7%)
1: sufficient material for limited cytologic interpretation but probably not 
representative, n
1
2: sufficient material for adequate cytologic interpretation but insufficient for 
histologic information, n
1
Histology (3‐5), n (%) 28 (93.3%)
3: sufficient material for limited histologic interpretation, n 8
4: sufficient material for adequate histologic interpretation but a low quality 
sample, na
9
5: sufficient material for adequate histologic interpretation and a high quality 
sample, nb
11
Contamination
1: contamination present in >50% of the slide, n 1 (3.3%)
2: contamination present in 25‐50% of the slide, n 3 (10.0%)
3: contamination present in <25% of the slide, n 26 (86.7%)
Amount of blood
1: significant, n 10 (33.3%)
2: moderate, n 11 (36.7%)
3: minimal, n 9 (30.0%)
aLow quality sample, total material within a 10 power field in length. 
bHigh quality sample, total material more than a 10 power field in length. 
T A B L E  3  Quality of histologic 
specimen (n = 30)
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We characterized and confirmed the CRCs by the in-
tense fluorescence of CK19 and tumorigenesis in vitro and 
in vivo. Immunofluorescence colony staining for CRCs was 
performed using an anti‐CK19 monoclonal antibody. The cy-
toplasm of cancer cells was clearly stained with this antibody. 
However, CRCs were not stained with amylase and insulin 
(Figure 3).
In the soft agar colony formation assay, CRCs formed col-
onies compared with the negative control by day 15 (Figure 
4A,B). In vivo, CRCs were implanted into the NOD/SCID 
mice. Implanted CRCs showed successful tumor engraftment 
and a 15 mm sized transplanted tumor was palpated on the 
side of the mouse after three months. Grafted tumors were 
surgically removed. CRC‐derived xenograft tissue demon-
strated homology for p53 expression compared with matched 
primary biopsy cancer tissue. And, sample had strong 
staining of ductal epithelial marker CK19, confirming that 
xenograft sample was origined from huam ductal adenocarci-
noma. (Figure 4C‐D).
We cultured CRCs over 20 passages after establishment. 
Initial experiments related to establishment were performed 
within two passages including immunofluorescence. Mouse 
implantation was performed at 15 passages.
Regarding key oncogenic mutations, KRAS mutation anal-
ysis was performed using PCR. All eight CRCs established 
using EUS‐FNB showed a codon‐12 KRAS mutation: G12D 
(n = 5), G12V (n = 2), G12R (n = 1) (Table 4). Research 
for patient‐derived model establishment and drug sensitivity 
testing using established conditionally reprogrammed cell 
lines is currently ongoing and holds promising preliminary 
results (H.S. Lee, S.J. Park, J. Lee, M.J. Chung, J.Y. Park, 
S.W. Park, S.Y. Song, J.M. Han, S. Bang, unpublished data). 
We performed targeted deep sequencing to confirm the iden-
tity of the genetic feature of CRCs compared to the original 
tumor. In the data, KRAS mutation signature of the CRCs 
(p.G12D) correlated with the KRAS mutation found in the 
patient's primary tumor (p.G12D).
4 |  DISCUSSION
Most pancreatic cancer patients are ineligible for the only 
curative treatment, surgical resection. Therefore, it is impor-
tant to establish pancreatic cancer cell lines using pancreatic 
biopsy samples for further molecular analysis and finding 
potential therapeutic targets. In this study, pancreatic cancer 
conditionally reprogrammed cell lines were successfully and 
rapidly created by means of EUS‐FNB sampling.
We checked the KRAS mutation in CRCs to confirm 
whether the CRCs reflect the original characteristics of 
PDAC. In previous studies, activated pathogenic variants 
in the proto‐oncogene KRAS were present in 90% of pa-
tients with PDAC,1,2 and the identified KRAS mutation was TA
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representative in PDAC with diagnostic and prognostic sig-
nificance. Several studies have validated the preclinical cell 
line models by identifying the key mutation, KRAS.12-14 In 
this study, an activated KRAS mutation was present in 100% 
of all established CRCs. Even if the results were not described 
in this manuscript, we performed whole exome sequencing 
for five patients (Hee Seung Lee, unpublished data). We con-
firmed that four patients showed additional p53 mutation be-
sides KRAS and one patient had p53 and CDKN2A mutation.
Because of intertumor heterogeneity, different patient‐de-
rived models had dissimilar genomic properties and treatment 
response even if most cell lines shared the key oncogenic 
KRAS mutation with their original tissue. Patient‐derived 
cell lines showed different drug responses to the therapeutic 
agent. To determine the inhibitory effects of gemcitabine on 
each CRC’s proliferation, we measured the IC50 of gemcit-
abine. YPAC‐16 was more sensitive to the growth‐inhibitory 
effect of gemcitabine (IC50 <1 μmol/L) than YPAC‐28 (IC50 
>100 μmol/L) (Figure 5). After all, progression free survival 
of patients who underwent gemcitabine‐based palliative che-
motherapy was comparable to the results of drug screening 
assay (Figure 5). Therefore, patient‐derived cell lines estab-
lishment may be a fundamental tool for personalized diagnosis 
and treatment in PDAC. This FNB sampling‐derived CRC cre-
ation is of great importance because we will ultimately reach 
personalized treatment via drug screening or toxicity test.
Until now, several preclinical models have been used for 
drug sensitivity tests, subtype specific functional analysis, and 
drug development for various cancers, including PDAC.3,15,16 
Previous studies have reported their results using patient‐de-
rived xenografts (PDX) as representative preclinical mod-
els. However, PDX takes many months to establish and is 
difficult to use for high‐throughput screening in cancer pa-
tients.3 Because of these limitations, a recent patient‐derived 
cancer cell line model, CRCs, are extensively used in cancer 
research.11,15,17,18 CRCs induce the propagation and immor-
talization of human tumor epithelial cells and generate pa-
tient‐specific cell lines within 2 or 4 weeks.10,11 Considering 
that small tissues from biopsy can be a source of primary 
cell lines using the CRC technique, EUS‐FNB should also be 
evaluated as a source of primary cancer cell lines.
We need to know which EUS‐related component is asso-
ciated with the improved performance of EUS‐guided tissue 
acquisition for establishment of primary cancer cell lines. 
With regards to optimal needle type, this study showed that 
a 20‐gauge needle was suitable for obtaining histologic core 
via EUS and developing the patient‐derived cell line model. 
In a previous study, to increase the diagnostic accuracy and 
acquire a histologic core, a side port needle was introduced.19 
Further, a newly designed needle featuring the ProCoreTM 
reverse bevel technology showed an additive effect for ade-
quate tissue acquisition.20,21 Even though several studies re-
ported the appropriate EUS‐guided biopsy needle to obtain 
a sufficient tumor sample in pancreatic cancer, those studies 
did not show the detailed quality of the samples using an 
objective score.4 In the present study, we showed relatively 
F I G U R E  3  Characterization of the 
intensely fluorescent cells in conditionally 
reprogrammed cells. α‐amylase 
(sc‐25562, rabbit polyclonal; Santa Cruz 
Biotechnology), dilution 1:100, resolution 
rate 200x; cytokeratin 19 (A53‐B/A2: 
sc‐6278, mouse monoclonal; Santa Cruz 
Biotechnology), dilution 1:100, resolution 
rate 200x; insulin (sc‐8033, mouse 
monoclonal; Santa Cruz Biotechnology), 
dilution 1:100, resolution rate 200x; 
vimentin (V9: sc‐6260, mouse monoclonal; 
Santa Cruz Biotechnology), dilution 1:100, 
resolution rate 200x
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high diagnostic accuracy (93.3%) using the 20‐gauge nee-
dle, and a more favorable result with regards to obtaining 
the histologic core (93.3%). One of the reasons for the suc-
cessful histologic core acquisition is the structural feature 
of the 20‐gauge needle with its side hole and cutting bevel. 
Further, the improved flexibility of the needle helped endos-
copists to handle it. With regards to the optimal number of 
needle passes, the relationship between the quality of tissue 
and the total number of passes is shown in Table S1. There 
was no statistically significant difference associated with the 
acquisition of the histologic core according to the number 
of needle passes after two times (two times vs three times, 
P  =  0.580). In the future, well‐designed prospective stud-
ies are needed to confirm the independent factors related to 
CRCs formation.
Most preclinical pancreatic cancer models were estab-
lished using the tissue samples from surgical resection. 
With recent technological improvements in EUS‐guided 
biopsy, several studies have tried to use biopsy samples in 
pancreatic cancer research. Gleeson et al22-24 showed that 
EUS‐guided tissue sampling revealed a majority of key on-
cogenic mutations in pancreatic cancer and the result was 
paired with surgical resection specimens through targeted 
next generation sequencing.22 Allaway et al23 developed 
PDX models using EUS‐guided biopsy in 29 patients who 
were diagnosed with PDAC and performed genomic char-
acterization for drug screening. Using in vitro drug sen-
sitivity and genomic studies, establishing patient‐derived 
cell lines via EUS‐FNB may help to identify and validate 
new targets or markers for the diagnosis and treatment of 
PDAC in the future.
To our knowledge, the present study is the first pro-
spective study to use EUS‐guided biopsy samples via 
CRC technique to establish a patient‐derived cancer 
model in pancreatic adenocarcinoma. A limitation of the 
study is that despite washing the specimens with saline to 
decrease the amount of blood in the specimen, the pro-
portion of patients with significant amount of blood in the 
specimen was 33.3%, although it did not prevent patho-
logic interpretation and the establishment of patient‐de-
rived cell lines. The to‐and‐fro movement of the FNB 
needle for >20 times may explain the amount of blood in 
the specimen. Second, the present study has a small sam-
ple size. However, this study is a pilot study to establish 
patient‐derived pancreatic cancer cell lines from small bi-
opsy samples using a CRCs technique. Large sample size 
studies using CRCs technology are currently undergoing 
with whole genome analysis for patient‐derived CRCs. 
F I G U R E  4  Tumorigenesis in vitro and in vivo. (A, B), In vitro tumorigenesis, Soft agar colony formation assay. (A) Negative control, (B) 
tumor cell formation at day 15; (C‐E) In vivo tumorigenesis and representative histology of xenografts. Hematoxylin and eosin staining showed 
that the implanted patient‐derived CRCs had a ductal structure. (C) In vivo tumorigenesis, 5‐week‐old male nonobese diabetic/severe combined 
immunodeficiency mice; (D) CRC‐derived xenograft tissue demonstrated homology for p53 expression compared with matched primary biopsy 
cancer tissue. The Ductal epithelial marker CK19 is positive in CRC‐derived xenograft by IHC stain
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Finally, less number of samples (<3 samples) were used 
for in vivo tumorigenesis and chemosensitivity test in 
this study. We studied this examination of patient‐derived 
cell lines establishment by EUS‐FNB and confirmation 
of 20G needle sufficiency for cell line formation. Only 
representative cases were used for typical findings and 
confirmation. Using more surgical tissue, metastatic liver 
tissue, and EUS‐biopsy, CRC establishment will warrant 
the successful use of patient‐derived subclinical model in 
the future.
In conclusion, EUS‐FNB is a reliable and accurate diag-
nostic test for malignant pancreatic lesions, especially for the 
establishment of preclinical models in patients with PDAC. 
It may be utilized for anticancer drug screening and genomic 
studies for personalized treatment. With in vitro drug sensi-
tivity and genomic studies, established patient‐derived cell 
lines can be used in the identification of new targets for diag-
nosis and treatment of pancreatic cancer.
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